2nd China International In Vitro Diagnostics Technology and Industry Development Summit (IVDS 2013)

  • 23-25 Aug 2013
  • Everbright Convention & Exhibition Center, Shanghai, China

Description

In Vitro Diagnostics Technology and Industry Development Summit (IVDS) covers topics such as:

  • Clinical Application of MDx
    • Infectious Disease and Rapid Detection
    • Cancer Diagnosis & Prognosis
    • Molecular Diagnosis of Cardiovascular and Cerebrovascular Disorders
    • Genetic Testing for Inherited Disorders and Prenatal Diagnostics
    • Diagnostics for CNS Diseases and Other Severe Diseases
  • Leading Research Discoveries and Technologies
    • Trends in Molecular Diagnostics. Personalized Medicine
    • Point-of-Care Diagnostic Systems
    • Biomarker Discovery & Translation
    • Companion Diagnostics
    • Next Generation Genome/DNA Sequencing Technology
    • Nucleic Acid Amplification based Technologies
    • Circulating Tumor Cells and Single Cell Analysis
    • Cytogenetics and Fluorescent In Situ Hybridization (FISH)
    • Micro- and Nanofluidics Technology and Applications
    • Biochips, Biosensors, and Nanobiotechnology in Medical Diagnosis
    • Medical Imaging
    • Mass Spectrometry in Clinical Diagnostics
    • Sample Prep and Target Enrichment
  • Technical, Commercial and Regulatory Challenges
    • Development & Commercialisation of IVD
    • Regulatory & Policy Update
    • Collaboration & Advances in Personalized Healthcare & MDx
    • Partnership & Investment Opportunities
    • Market Development & Growth Strategies
    • Innovations & Technology Breakthroughs

Past Events

Important

Please, check "China International In Vitro Diagnostics Technology and Industry Development Summit (IVDS)" official website for possible changes, before making any traveling arrangements

Event Categories

Health & Medicine: Healthcare, Medical device, Medical technology, Pharma
Science: Health sciences, Life Sciences & Biology
Technology: Biotechnology

Other Events with Similar Categories

Other Events with Similar Location or Organizer

Featured Conferences & Exhibitions

Articles / News / Press releases

Article content. Press on the above link to close

Title:

PIMA Point of Care CD4 Cell Count Machines in remote maternal, newborn and child health (MNCH) settings: Lessons learnt from seven Districts in Zimbabwe.

S. Mtapuri-Zinyowera1, E. Chiyaka2, W. Mushayi3, G. Musuka3, V. Chikwasha4, T. Zinyowera5, S. Bhatasara4, T. Chevo4, N. Muparamoto4, A. Mushavi5, F. Naluyinda-Kitabire3

1National Microbiology Reference Laboratory, Laboratory, Harare, Zimbabwe, 2National University of Science and Technology, Bulawayo, Zimbabwe, 3UNICEF, Harare, Zimbabwe, 4University of Zimbabwe, Harare, Zimbabwe, 5Ministry of Health and Child Welfare, Harare, Zimbabwe

Background

Several evaluations have been published that compare CD4 point-of-care machines to conventional flow cytometry methods yet a few have been done focusing on how PIMA POC CD4 machines actually performs in clinical settings.

Methods

A cross-sectional survey was conducted on 35 MNCH sites with the POC machine and 10 without in 7 Districts in Zimbabwe. There were a total of 346 interviews done with national and subnational stakeholders involved in procurement, distribution and use of the POC machine, among them trained users of the PIMA POC CD4 count machines at health facilities and clients. Additionally, data was also abstracted from 207 patient records from 35 sites with the PIMA POC CD4 count machines and 10 other comparative sites without the PIMA POC CD4 count machines. 

Results

The median time taken to initiate clients on ART was substantially less, 15days (IQR-1-149) for sites with a PIMA POC machine as compared to 32.7 days (IQR-1-192) at sites with no PIMA POC machine. Additionally, in order to enhance quality of service delivery there is need for a clearer training strategy.

Conclusion

The PIMA POC technology has contributed to the improvement of service delivery at site level through provision of a timely CD4 cell count to pregnant mothers in order to assess eligibility to ART for their own health and prevention of mother to child transmission of HIV.

References

  1. Balakrishnan P, Shanmugham S, Iqbal HS, Solomon SS, Mohanakrishnan J, Mayer KH and Solomon S. Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J Med Res. 134: 823-834; 2011
  2. Manabe YC, Wang Y, Elbireer A, Auerbach B and Castelnuovo B. Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. Plos one. 7(4):e34319; 2012.
  3. Jani VI, Sitoe NE, Alfai ER, Changa PL, Queredo JI, Rocha BM, Lehe JD and Peter TF. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. (378):1572-79; 2011.